🟢 MEDPAL AI is trading 6.82% up today after highlighting Mounjaro’s expanded cardiovascular-risk use

MEDPAL AI is trading at £4.70 (+6.82%) after highlighting FDA approval for Mounjaro to reduce cardiovascular risk.

• On September 1, 2026, MEDPAL AI said this expands potential GLP-1 usage beyond diabetes and weight management.
• The company said New Health dispenses Mounjaro through authorised Eli Lilly purchasing arrangements; estimated approximately 1.4 million potentially relevant UK adults.
• This is the clearest company-specific catalyst identified, although the announcement did not explicitly reference the share-price move.